Shattuck Labs, Inc. (STTK)

Market Cap	83.27M
Revenue (ttm)	1.33M
Net Income (ttm)	-95.02M
Shares Out	42.49M
EPS (ttm)	-2.24
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	29,581
Open	1.81
Previous Close	1.96
Day's Range	1.81 - 1.98
52-Week Range	1.33 - 4.77
Beta	1.21
Analysts	Strong Buy
Price Target	20.00 (+920.41%)
Earnings Date	Nov 9, 2023

About STTK

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. The company was incorporated in 2016 and is headquartered in Austin, Texas.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 9, 2020
• Employees: 105
• Stock Exchange: NASDAQ
• Ticker Symbol: STTK

Financial Performance

In 2022, Shattuck Labs's revenue was $652,000, a decrease of -97.83% compared to the previous year's $30.02 million. Losses were -$101.95 million, 126.7% more than in 2021.

Analyst Forecast

According to 2 analysts, the average rating for STTK stock is "Strong Buy." The 12-month stock price forecast is $20.0, which is an increase of 920.41% from the latest price.

Price Target

$20.0

(920.41% upside)

Analyst Consensus: Strong Buy